Cortexyme, Inc. Announces Closing of Initial Public Offering and the Exercise of the Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical
company pioneering a novel disease-modifying therapeutic approach to
treat a key underlying cause of Alzheimer’s and other degenerative
diseases, today announced the closing of its initial public offering of
4,412,000 shares of its common stock at the public offering price of
$17.00 per share, and the full exercise by the underwriters of their
option to purchase 661,800 additional shares of Cortexyme’s common
stock. The exercise of the option brings the total number of shares of
common stock sold by Cortexyme to 5,073,800 shares. The net proceeds
from Cortexyme’s initial public offering, including proceeds from the
exercise of the underwriters’ option to purchase additional shares, were
approximately $78.1 million, after deducting underwriting discounts and
commissions and estimated offering expenses payable by Cortexyme.
BofA Merrill Lynch and Credit Suisse Securities (USA) LLC acted as joint
book-running managers for the offering. Canaccord Genuity LLC and JMP
Securities LLC acted as co-managers.
A registration statement relating to these securities has been filed
with the Securities and Exchange Commission and was declared effective
on May 8, 2019. The offering was made solely by means of a prospectus
forming part of the effective registration statement. Copies of the
final prospectus relating to this offering may be obtained from any of
the following sources:
-
BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd
Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or
by phone at 1-800-294-1322 or by email at dg.prospectus_requests@baml.com; -
Credit Suisse Securities (USA) LLC, Attn: Prospectus Department,
Eleven Madison Avenue, 3rd Floor, New York, NY 10010, by telephone at
1-800-221-1037 or by email at usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of shares
of Cortexyme’s common stock in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or
jurisdiction.
About Cortexyme, Inc.
Cortexyme is a clinical stage pharmaceutical company pioneering a novel
disease-modifying therapeutic approach to treat a key underlying cause
of Alzheimer’s disease and other degenerative diseases. Cortexyme is
targeting a specific, infectious pathogen found in the brain of
Alzheimer’s patients and tied to neurodegeneration and neuroinflammation
in animal models. The company’s lead investigational medicine, COR388,
is the subject of the GAIN Trial, an ongoing Phase 2/3 clinical study in
patients with mild to moderate Alzheimer’s disease.
Forward-Looking Statements
Statements in this press release contain “forward-looking statements”
that are subject to substantial risks and uncertainties. Forward-looking
statements contained in this press release may be identified by the use
of words such as “anticipate,” “expect,” “believe,” “will,” “may,”
“should,” “estimate,” “project,” “outlook,” “forecast” or other similar
words. Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future events
that may not prove to be accurate. Factors that could cause actual
results to differ include, but are not limited to, the risks and
uncertainties described in the section titled “Risk Factors” in the
final prospectus related to the public offering filed with the
Securities and Exchange Commission. Forward-looking statements contained
in this announcement are made as of this date, and Cortexyme undertakes
no duty to update such information except as required under applicable
law.
Contacts
Chris Lowe
Chief Financial Officer
Cortexyme, Inc.
clowe@cortexyme.com
Hal Mackins
For Cortexyme, Inc.
hal@torchcomllc.com
(415)
994-0040